From the Journals

Diagnostic laparoscopy identifies ovarian cancers amenable to PCS


 

For women with suspected advanced epithelial ovarian cancer, diagnostic laparoscopy can help to distinguish between patients who could benefit from primary cytoreductive surgery (PCS) and those who might have better outcomes with neoadjuvant chemotherapy and interval cytoreductive surgery, according to investigators in the Netherlands.

In a randomized controlled trial exploring whether initial diagnostic laparoscopy could spare some patients from undergoing futile PCS, the investigators found that only 10% of patients assigned to diagnostic laparoscopy prior to PCS underwent a subsequent futile laparotomy, defined as residual disease greater than 1 cm following surgery. In contrast, 39% of women assigned to primary PCS had disease that might have been better treated by chemotherapy and interval surgery,

“In women with a plan for PCS, these data suggest that performance of diagnostic laparoscopy first is reasonable and that if cytoreduction to [less than] 1 cm of residual disease seems feasible, to proceed with PCS,” wrote Marrije R. Buist, MD of Academic Medical Center, Amsterdam, and colleagues.

Among women with International Federation of Gynecology and Obstetrics (FIGO) stage IIIC to IV epithelial ovarian cancer, survival depends largely on the ability of surgery to either completely remove disease, or to leave at best less than 1 cm of residual disease. However, aggressive surgery in patients with more extensive disease is associated with significant morbidities, the authors noted.

“If at PCS, extensive disease is present, surgery could be ceased, and neoadjuvant chemotherapy with interval surgery could be a good alternative treatment. Therefore, the identification of patients with extensive disease who are likely to have [more than] 1 cm of residual tumor after PCS, defined as a futile laparotomy, is important,” they wrote.

To test this idea, the investigators, from eight cancer centers in the Netherlands, enrolled 201 patients with suspected FIGO stage IIB ovarian cancer or higher, and randomly assigned them to undergo either initial diagnostic laparoscopy or PCS.

They found that 10 of the 102 patients (10%) assigned to diagnostic laparoscopy went on to undergo PCS that revealed residual disease greater than 1 cm, compared with 39 of the 99 patients (39%) assigned to PCS. This difference translated into a relative risk for futile laparotomy of 0.25 for diagnostic laparoscopy compared with PCS (P less than .001).

Only 3 (3%) patients in the diagnostic laparoscopy group went on to have both PCS and interval surgery, compared with 28 (28%) patients initially assigned to PCS (P less than .001).

The Dutch Organization for Health Research and Development supported the study. All but one coauthor reported having no potential conflicts of interest.

Recommended Reading

Subgroup may benefit from seribantumab for platinum-resistant ovarian cancer
MDedge Hematology and Oncology
Cancer survivors report two times greater medication use for anxiety and depression
MDedge Hematology and Oncology
Delaying cancer treatment for fertility preservation did not affect outcomes
MDedge Hematology and Oncology
Drug enhances carboplatin efficacy against ovarian cancer
MDedge Hematology and Oncology
Tips for avoiding nerve injuries in gynecologic surgery
MDedge Hematology and Oncology
Low rate of occult uterine malignancy with vaginal morcellation
MDedge Hematology and Oncology
Survey: More than half of gynecologic oncologists altered morcellation practices
MDedge Hematology and Oncology
Lower analgesic use after robotic pelvic surgery
MDedge Hematology and Oncology
FDA approves treatment for platinum-sensitive ovarian cancer
MDedge Hematology and Oncology
FDA approves rucaparib for BRCA-positive advanced ovarian cancer
MDedge Hematology and Oncology